Swedbank AB and various other entities including
Tidal Investments LLC, and
iA Global Asset Management Inc. have acquired substantial holdings in
West Pharmaceutical Services, Inc. (WST). However, some public retirement systems and asset management companies have lowered their holdings. Fluctuations in WST's performance have been notable, with some quarters meeting or exceeding expectations, while others have missed forecasts.
Customer destocking challenges have led to the company downscaling its 2024 financial outlook. Despite these challenges, the company remains a
dividend aristocrat. The company has seen considerable
options volume and released new products like
Daikyo Crystal Zenith® Ready-to-Use Nested Vials further illustrating their innovation potential. The firm's Q2 2024 earnings fell short of estimates, due to
weak annual results forecast and
lower demand, causing the firm's stock to hit a 52-week low. Nevertheless, WST remains a solid pick for long-term investors given its overall strong financials and continuous endeavors in diversifying its product range.
West Pharmaceutical Services WST News Analytics from Tue, 25 Jan 2022 08:00:00 GMT to Sun, 04 Aug 2024 12:12:57 GMT -
Rating -2
- Innovation 5
- Information 6
- Rumor 3
